Outcomes of De Novo Use of Generic Tacrolimus (Adoport (R)) in Living-Related Kidney Transplantation: A Single-Center, Real-Life Experience of 5 Years

EREN SADİOĞLU R., Karaoglan M., AKTAR M., AKKAN EREN Ş., KOCAAY A. F., TÜZÜNER A., ...Daha Fazla

TURKISH JOURNAL OF NEPHROLOGY, cilt.30, sa.4, ss.255-261, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 4
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5152/turkjnephrol.2021.20013
  • Dergi Adı: TURKISH JOURNAL OF NEPHROLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.255-261
  • Anahtar Kelimeler: Kidney transplantation, tacrolimus, generic drug, treatment costs, CONVERSION, RECIPIENTS, PHARMACOKINETICS, FORMULATION
  • Ankara Üniversitesi Adresli: Evet

Özet

Objective: Tacrolimus (TAC), the mainstay immunosuppressive drug in kidney transplantation, is a narrow therapeutic index drug and has strict bioequivalence (BE) acceptance criteria adopted by regulatory agencies. Possible acute rejection resulting from the use of a generic drug is the main matter of concern for responsible physicians. We aimed to show the possible differences in drug dosages and serum concentrations and to share our experience on this subject.